Indinavir is a widely prescribed protease inhibitor in the treatment of HIV infection. It has been associated with nephrolithiasis, crystalluria and tubulointerstitial nephritis. Nelfinavir is another protease inhibitor used successfully in AIDS treatment. The objective of this study was to evaluate the effect of both indinavir and nelfinavir individually, and in association with trimethoprim-sulfamethoxazole (TMP/SMX), on renal function in Wistar rats.
Methods
Doses of indinavir (80 mg/kg body weight [BW] daily), nelfinavir (75 mg/kg BW daily) and TMP/SMX (100 mg TMP/kg BW daily) were given by gavage for 15 days. Seven groups were studied: control, vehicle, TMP/SMX, indinavir, indinavir+TMP/SMX, nelfinavir, and nelfinavir+TMP/SMX.
Results
No changes were observed in body weight, urine volume and blood pressure. The vehicle group did not differ from the control group. TMP/SMX induced a small decrease in inulin clearance with no tubular alterations. Indinavir decreased inulin clearance (indinavir: 0.48 ±0.03 vs control: 0.93 ±0.08, P<0.001) and renal blood flow (indinavir: 6.2 ±0.2 vs control: 8.0 ±0.3, P<0.05). These effects were potentiated by TMP/SMX, which produced high vasoconstriction associated with alterations in tubular functions, characterised by increased fractional excretion of sodium (indinavir+TMP/SMX: 1.14 ±0.16 vs control: 0.39 ±0.07, P<0.01). Nelfinavir either alone or in combination with TMP/SMX did not change the renal function of the rats.
Conclusion
These results suggest that indinavir nephrotoxicity in rats is potentiated by TMP/SMX and that nelfinavir alone or in combination with TMP/SMX is not nephrotoxic.
References
1.
KoppJ.B., MillerK.D., MicanJ.A.M., FeuersteinI.M., VaughanE.R.N., BakerC., PannellL.K., & FalcoonJ.Crystalluria and urinary tract abnormalities associated with indinavir. Annals of Internal Medicine1997; 127: 119–125.
2.
GagnonR.F., TecimerS.N., WattersA.K., & TsoukasC.M.Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. American Journal of Kidney Diseases2000; 36: 507–515.
3.
PerazellaM.A.Crystal-induced acute renal failure. American Journal of Medicine1999; 106: 459–465.
4.
JaradatM., PhillipsC., YunM.N., CushingH., & MoeS.Acute tubulointerstitial nephritis attributable to indinavir therapy. American Journal of Kidney Diseases2000; 35: E16.
5.
CattelanA.M., TrevenzoliM., NasoA., MeneghettiF., & CadrobbiP.Severe hypertension and renal atrophy associated with indinavir. Clinical Infectious Diseases2000; 30: 619–621.
6.
BoubakerK., SudreP., BallyF., VogelG., MeuwlyJ.Y., GlauserM.P., & TelentiA.Changes in renal function associated with indinavir. AIDS1998; 12: F249–F254.
7.
SchwarzA., & Perez-CantoA.Nephrotoxicity of antiinfective drugs. International Journal of Clinical Pharmacology Therapy1998; 36: 164–167.
8.
AndreevE., KoopmanM., & AriszL.A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible. Journal of Internal Medicine1999; 246: 247–251.
9.
PerazellaM.A., & MahnensmithR.L.Trimetoprimsulfamethoxazole: hiperkalemia is an important complication regardless the dose. Clinical Nephrology1996; 46: 187–192.
10.
Bardsley-ElliotA., & PloskerG.L.Nelfinavir: an update on its use in HIV infection. Drugs2000; 59: 581–620.
11.
ElionR., KaulS., KnuppC., AdlerM., CrossA.P., DunkleL.M., & KelleherT.The safety profile and antiviral activity of the combination of stavudine, didanosine and nelfinavir in patients with HIV infection. Clinical Therapy1999; 21: 1853–1863.
12.
SchorN., IchikawaI., Rennke HG TroyJ.L., & BrennerB.M.Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney International1981; 19: 288–296.
13.
AssisS.M., MonteiroJ.L., & SeguroA.C.L-arginine and allopurinol protect against cyclosporine nephrotoxicity. Transplantation1997; 63: 1070–1073.
14.
PiscitelliS.C., FlexnerC., MinorJ.R., PollisM.A., & MasurH.Drug interactions in patients with human immunodeficiency virus. Clinical Infectious Diseases1996; 23: 685–693.
15.
MooreK.H.P., Yuen GJ RaaschR.H., EronJ.J., MartinD., MydlowP.K., & HusseyE.K.Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clinical Pharmacology Therapy1996; 59: 550–558.
16.
SturgillM.G., SeiboldJ.R., BoruchoffS.E., YehK.C., HaddixH., & DeutschP.Trimethoprim-sulfamethoxazole does not affect the steady state diposition of indinavir. Journal of Clinical Pharamcology1999; 39: 1077–1084.
17.
AraujoM., & SeguroA.C.Magnesium supplementation attenuates indinavir nephrotoxicity. Journal of the American Society of Nephrology2001; 12: 797A.
18.
SmithE.J., LightJ.A., FiloR.S., & YumM.N.Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients. Journal of the American Medical Association1980; 244: 360–361.
19.
RingdenO., MyrenforsP., KlintmalmG., TydenG., & OstL.Nephrotoxicity by co-trimoxazole and cyclosporine in transplanted patients. The Lancet1984; 1: 1016–1017.
20.
PaapC.M., & NahataM.C.Clinical use of trimethoprim-sulfamethoxazole during renal dysfunction. DICP – The Annals of Pharmacotherapy1989; 23: 646–654.
21.
IzzedineH., DiquetB., Launay-VacherV., JouanM., TheouN., & DerayG.Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency. AIDS1999; 13: 1989.
